| Posted: Jan 31st, 2013 | |
MagForce Starts Nanomedicine Research Project With University of Bremen |
|
| (Nanowerk News) MagForce AG, a leading medical technology company in the field of nanomedicine in oncology, today announced the start of a research project with the University of Bremen, Center for Environmental Research and Sustainable Technology, for the development of magnetic iron oxid particles with improved efficiency. The novel particles will allow a more efficient treatment of abdominal cancers, such as prostate and pancreatic cancer. A more efficient magnetic fluid and a pilot manufacturing facility will result from the collaboration. | |
| The project will receive funding from the German Mittelstand Innovation Program (ZIM) which is managed by the German Federal Ministry of Economics and Technology and will run for two years. | |
| “We are excited to be working with Prof Dr Jorg Thöming, who is an internationally renowned expert in the area of process engineering, as a cooperation partner. This project is perfectly in-line with MagForce’s new strategy to conduct early-stage research and development collaborations with academic institutions”, commented Prof Dr Hoda Tawfik, COO and co-CEO of MagForce AG. “In August 2012, we temporarily put all internal early-stage research and development on hold to focus the Company’s resources on establishing our NanoTherm® therapy in the market. This project gives us the opportunity to develop the next generation of NanoTherm® that will significantly improve the treatment of abdominal cancers.” Prof Dr Jorg Thöming comments: “I am excited to start the collaboration in the nanotechnology area with MagForce, an innovative nanomedicine company. The exploitation of synergies between our scientists is very promising.” | |
| About MagForce AG | |
| MagForce AG is a leading medical technology company in the field of nanomedicine in oncology. The Company's proprietary, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm®, NanoPlan®, and NanoActivator™ are trademarks of MagForce AG in select countries. For more information, please visit www.magforce.com. |
| Source: MagForce (press release) |
Translate this article:
Check out these other trending stories on Nanowerk:
|
Subscribe to a free copy of one of our daily |